Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis
Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis
Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis
Submitted by
admin
on July 23, 2018 - 9:42am
Source:
CP Wire
News Tags:
Alnylam
Patisiran
hereditary ATTR amyloidosis
Headline:
Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis
snippet:
Changes in familial amyloid polyneuropathy and polyneuropathy disability were significant
Earlier indirect comparison of patisiran vs rival indicated patisiran superiority
Do Not Allow Advertisers to Use My Personal information
